Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › GLENMARK

GLENMARK

Glenmark Pharmaceuticals Limited
Mid-capPharma ↗

What the six lenses say about GLENMARK — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹2451.9
2026-09-08
VWAP · 1Y anchor
₹2104
+16.5% from VWAP
P/E · TTM
50.8×
TTM EPS ₹48.3
52-week range
91%
position low→high
RSI(14)
62
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How GLENMARK’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
7.0
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Mid-cap cohortDRaw
TechnicalD1090›

The actual numbers

Price vs VWAP (1y)+16.5%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+13.2%
Price vs 50-EMA+5.5%
RSI(14)62
RS vs Nifty 500 · 3M+8.2%
RS vs sector · 3M+2.2%
52-week range91%
Volume vs 30d avg0.85×
Volume vs 60d avg0.82×
ATR(14) · volatility63.1
Bollinger width · vol contraction0.133
FundamentalD974›

The actual numbers

Return on equity (ROE)30.5%
Return on capital (ROCE)39.8%
Operating margin12.9%
Net margin8.0%
Revenue growth · YoY+27.5%
EPS growth · YoY+30.1%
Debt / equity0.06×

Full 8-quarter history in the financials table below.

ValuationD38›

The actual numbers

P/E (TTM)50.8×
TTM EPS₹48.3
52-week range91%
CatalystD967›

The actual numbers

Earnings & momentum96
Capital actions13
Governance70

Every filing in the corporate-announcements panel below.

FlowD450›

The actual numbers

Promoter holding46.6%
Delivery · 30d avg44.7%
Up/down-day asymmetry-2.8pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Mid-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D10 + D4 ) ÷ 2 = 7.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
86
Conviction score 86/100 · avg-decile strength 7.0/10
Conviction score86/100›
TechnicalD10›
FundamentalD9›
ValuationD3›
CatalystD9›
FlowD4›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+1.1pp
+0.1pp
+11.5pp
+9.8pp
+18.2pp
+23.5pp
Nifty 500
Broad-market baseline
+1.0pp
+0.1pp
+10.4pp
+8.2pp
+12.4pp
+18.3pp
Sector
Own-sector index
—
—
+7.6pp
+2.2pp
-0.7pp
-2.5pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

GLENMARK daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
2451.90+14.70

Relative strength

RS vs baseline · rebased to 100

GLENMARK ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
146.02+1.49

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)3,2443,4343,3883,2563,2646,0473,9013,771
↳ change QoQ—+5.8%-1.3%-3.9%+0.2%+85.3%-35.5%-3.3%
EBITDA (₹cr)6206416315615812,360870763
EBITDA margin19.1%18.7%18.6%17.2%17.8%39.0%22.3%20.2%
PAT (₹cr)340354348447610403301
↳ change QoQ—+4.2%-1.8%-98.9%+1075.0%+1197.9%-33.9%-25.3%
Net margin10.5%10.3%10.3%0.1%1.4%10.1%10.3%8.0%
EPS (₹)12.0612.5512.330.161.6621.6314.2910.68
D/E————————
YoY growth · Mar '26Revenue +15.8% YoYPAT +7425.0% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 21 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 20 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 13 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Options to purchase securities
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 3 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Jul '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Jul '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 31 Jul '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Jul '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 28 Jul '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 21 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Jul '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds GLENMARK

Mutual funds holding GLENMARK (10)

FundWeightAUM ₹crGrade
HDFC Mid Cap Gr2.85%1,05,143
SBI Arbitrage Opportunities Reg Gr0.56%46,803
ICICI Prudential Arbitrage Reg Gr0.81%34,180
Bandhan Small Cap Reg Gr0.66%31,103
HDFC Large and Mid Cap Gr0.78%30,099
Invesco India Arbitrage Gr0.74%29,629
Aditya BSL Arbitrage Gr0.51%26,939
Bandhan Large & Mid Cap Gr1.26%19,777
Nippon India Arbitrage Gr1.02%16,916
Edelweiss Arbitrage Fund Reg Gr1.17%15,139

ETFs holding GLENMARK (10)

ETFWeightGrade
Nippon India Nifty Pharma ETF3.40%
DSP Nifty Healthcare ETF2.93%
Axis NIFTY Healthcare ETF2.92%
Aditya BSL Nifty Healthcare ETF2.92%
ICICI Pru Nifty Healthcare ETF2.92%
Mirae Asset Nifty 500 Healthcare ETF2.42%
Motilal Oswal BSE Healthcare ETF2.07%
Motilal Oswal Nifty Midcap150 Momt 50ETF1.98%
Kotak Nifty 200 Momentum 30 ETF1.61%
Groww Nifty 500 Momentum 50 ETF1.57%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma